Secondary Hypogonadism Clinical Trial
Official title:
A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration
The purpose of ZA-301 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T<300 ng/dL) and normal sperm concentration, compared to changes with placebo. Subjects must not have previously been treated with testosterone products within the last 6 months.
Protocol ZA-301 is a randomized, double-blind, placebo-controlled multi-center Phase 3 study
to evaluate normalization of morning testosterone levels in overweight men with acquired
hypogonadotropic hypogonadism and normal baseline sperm concentrations. The study requires
10 to 12 clinic visits (2 for eye exams), and is approximately 4 to 5½ months in duration.
Subjects will be treated for 12-18 weeks. At Visit 3 (Week 6) subjects who do not achieve
morning T values ≥300 ng/dL will be up-titrated to 25 mg. Placebo subjects may be sham
titrated. Up-titrated subjects will receive an additional 6 weeks of treatment (18 weeks
total). A schedule of procedures and assessments is displayed in Section 4. The study will
enroll up to 152 male subjects, up to 114 randomized to treatment with Androxal and up to 38
randomized to placebo, in a 3:1 ratio. Subjects must not have used any prior testosterone
treatments within the last 6 months.
Eligible subjects must have 2 consecutive assessments of morning T below 300 ng/dL and LH
below 9.4 mIU/mL. They will provide 2 sperm samples at baseline, at least 2 days apart,
another 2 after 12 weeks of treatment, and up-titrated subjects will provide an additional 2
samples at the end of treatment. After 12 weeks of treatment (V5) all subjects will undergo
serial T assessment for determination of the Cavg. Safety assessments will include
collection of adverse events, eye examinations, physical examinations and clinical
laboratory assessments.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01454011 -
The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups
|
Phase 4 | |
| Completed |
NCT01191320 -
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
|
Phase 2 | |
| Completed |
NCT01739582 -
An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
|
Phase 3 | |
| Completed |
NCT01739595 -
Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
|
Phase 3 | |
| Active, not recruiting |
NCT02443090 -
Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men
|
Phase 2 | |
| Completed |
NCT01534208 -
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
|
Phase 3 | |
| Completed |
NCT01067365 -
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
|
Phase 3 | |
| Completed |
NCT00467870 -
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
|
Phase 3 | |
| Completed |
NCT00962637 -
Study to Evaluate the Safety and Efficacy of Androxalâ„¢ Treatment in Men With Secondary Hypogonadism
|
Phase 3 | |
| Completed |
NCT01386606 -
The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)
|
Phase 2 | |
| Completed |
NCT00706719 -
To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
|
Phase 2 | |
| Completed |
NCT00911586 -
Pharmacokinetic Study to Determine Time to Steady-state
|
Phase 2 | |
| Completed |
NCT01993225 -
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
|
Phase 3 | |
| Completed |
NCT01993212 -
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
|
Phase 3 | |
| Completed |
NCT01270841 -
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
|
Phase 2 | |
| Completed |
NCT02274181 -
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
|
Phase 1 | |
| Completed |
NCT01923870 -
Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT01923857 -
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
|
Phase 1 |